3. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. 4. https://www.sabcs.org/ 5. Ann Oncol. 2023 Jun 1. IF: 51.769. ESMO Expert Consensus Statements (ECS) on the definition, di...
乳腺癌HER2精准分类——细化HER2-Low免疫组化的染色模式 2022年8月,诺丁汉大学医院NHS Trust的Emad A Rakha教授团队在Histopathology杂志上发表《Refining the definition of HER2-low class in invasive breast cancer》,对HER2低表达判读标准进行细化...
[7] Wolff AC, et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerASCO-College of American Pathologists Guideline Update. J Clin0nco1.2023:JC02202864. [8] Tarantino P. et al. ESMO expert consensus statements (ECS) on thedefinition.diagnosis, and management of HER2-low ...
3. Modi S, Jacot W, Yamashita T, et al. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. N Engl J Med. 2022;387(1):9-20. 4. https://www./ 5. Ann Oncol. 2023 Jun 1. IF: 51.769. ESMO Expert Consensus Statements (ECS) on the definition, diagnosis, ...
Luminal B HER2-Negative and TN surrogate subtypes that met the definition of HER2-Low had a higher frequency of G3 than their non-HER2-Low counterpart.Conclusions:In the population analyzed, a considerable percentage of cases meet the definition of HER2-Low. This has relevant therapeutic ...
Breast cancer has been traditionally classified as either human epidermal growth factor receptor 2 (HER2)-positive or HER2-negative based on immunohistoche
[13]Tarantino P,Viale G,Press MF,et al.ESMO expert consensus statements(ECS)on the definition,diagnosis,and management of HER2-low breast cancer.Ann Oncol.2023;34(8):645-659.doi:10.1016/j.annonc.2023.05.008 [14]Wolff AC,Somer...
According to this definition, HER2- only includes those patients with an IHC score of 0. In HER2low breast cancer cases, the number of receptors is low compared to cases with HER2 amplification11. Overall, it is estimated that around 55% of all breast cancers is HER2low5,7. Hence, it ...
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes J Clin Oncol, 30 (2012), pp. 1796-1804 View in ScopusGoogle Scholar 34 Y. Shao, Y. Yu, Z. Luo, et al. Clinical, pathological complete response, and pr...
According to this definition, HER2- only includes those patients with an IHC score of 0. In HER2low breast cancer cases, the number of receptors is low compared to cases with HER2 amplification11. Overall, it is estimated that around 55% of all breast cancers is HER2low5,7. Hence, it ...